Drug intelligence / Profile preview

10-1074-LS

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

10-1074-LS is a modified version of the broadly neutralizing antibody (bNAb) 10-1074, engineered with LS mutations to extend its half-life. It targets the base of the V3 loop and surrounding glycans on the HIV-1 envelope glycoprotein. This long-acting antibody is being developed for HIV treatment and prevention, with potential applications in maintaining viral suppression during treatment interruptions and reducing the viral reservoir.

Other names: ZAB

Targets

HIV-1 envelope glycoprotein V3 glycan supersite (GDIR motif)

Beyond the preview

Go deeper on 10-1074-LS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 10-1074-LS.

Explore the full profile